Drug Profile
Research programme: anticancer antibodies - Attenuon/Kirin Brewery
Latest Information Update: 11 Jul 2007
Price :
$50
*
At a glance
- Originator Attenuon LLC; Kirin Brewery
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Feb 2004 Preclinical trials in Cancer in USA (unspecified route)